Long-term effect of supporting immunotherapy in a patient with metastatic small cell lung cancer
https://doi.org/10.17650/2782-3202-2024-4-3-45-49
Abstract
About 15 % of lung tumors are small cell lung cancer. Because of its extremely poor prognosis with a median overall survival of 10 months, and the long absence of new treatment options beyond the combination of platinum and etoposide (EP), the introduction of immunotherapy has been a significant development in the treatment of this disease. IMpower133 was the first phase III trial demonstrated a statistically significant increase in median overall survival in the atezolizumab group from 10.3 to 12.3 months. Our clinical case demonstrates the efficacy of an EP with atezolizumab. The patient got 6 courses of EP with atezolizumab and 29 courses of atezolizumab maintenance immunotherapy, indicating the efficacy and tolerability of this combination.
Supporting agencies: The work was performed without external funding
About the Authors
A. A. Filimonov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
Aleksii Alekseevich Filimonov
143081; 111 1st Uspenskoe Shosse; Moscow region; Lapino
N. M. Kutakov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
143081; 111 1st Uspenskoe Shosse; Moscow region; Lapino
D. A. Chekini
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
143081; 111 1st Uspenskoe Shosse; Moscow region; Lapino
References
1. Sung H., Ferlay J., Siegel R.L. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209–49. DOI: 10.3322/caac.21660
2. Puglisi M., Dolly S., Faria A. et al. Treatment options for small cell lung cancer – do we have more choice? Br J Cancer 2010;102(4):629–38. DOI: 10.1038/sj.bjc.6605527
3. Yang S., Zhang Z., Wang Q. Emerging therapies for small cell lung cancer. J Hematol Oncol 2019;12(1):47. DOI: 10.1186/s13045-019-0736-3
4. Peifer M., Fernández-Cuesta L., Sos M.L. et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012;44(10):1104–10. DOI: 10.1038/ng.2396
5. Reck M., Bondarenko I., Luft A. et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013;24(1):75–83. DOI: 10.1093/annonc/mds213
6. Reck M., Luft A., Szczesna A. et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol 2016;34(31):3740–8. DOI: 10.1200/JCO.2016.67.6601
7. Horn L., Mansfield A.S., Szczęsna A. et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018;379(23):2220–9. DOI: 10.1056/NEJMoa1809064
8. Paz-Ares L., Dvorkin M., Chen Y. et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 2019;394(10212):1929–39. DOI: 10.1016/S0140-6736(19)32222-6.
9. Paz-Ares L., Garassino M.C., Chen Y. et al. Durvalumab ± tremelimumab + platinum-etoposide in extensive-stage small cell lung cancer (CASPIAN): outcomes by PD-L1 expression and tissue tumor mutational burden. Clin Cancer Res 2024;30(4):824–35. DOI: 10.1158/1078-0432.CCR-23-1689
Review
For citations:
Filimonov A.A., Kutakov N.M., Chekini D.A. Long-term effect of supporting immunotherapy in a patient with metastatic small cell lung cancer. MD-Onco. 2024;4(3):45-49. (In Russ.) https://doi.org/10.17650/2782-3202-2024-4-3-45-49
Views:
142
Email this article 